Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function
Summary: Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-08-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004221008774 |
| id |
doaj-ef21c1f54c1d40ee9069626d0d29b605 |
|---|---|
| record_format |
Article |
| spelling |
doaj-ef21c1f54c1d40ee9069626d0d29b6052021-08-22T04:30:48ZengElsevieriScience2589-00422021-08-01248102909Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell functionDana Al Rijjal0Ying Liu1Mi Lai2Youchen Song3Zahra Danaei4Anne Wu5Haneesha Mohan6Li Wei7Francisco J. Schopfer8Feihan F. Dai9Michael B. Wheeler10Department of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, Canada; Division of Advanced Diagnostics, Metabolism, Toronto General Research Institute, ON, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, Canada; Division of Advanced Diagnostics, Metabolism, Toronto General Research Institute, ON, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, CanadaDepartment of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, ChinaDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA; Pittsburgh Liver Research Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USADepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, CanadaDepartment of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, Canada; Division of Advanced Diagnostics, Metabolism, Toronto General Research Institute, ON, Canada; Corresponding authorSummary: Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes, and pancreatic beta cell function are not well understood. In the present study, mice were treated with Vascepa or Lovaza for one week prior to six weeks of high-fat diet feeding. Vascepa but not Lovaza led to reduced insulin resistance, reduced fasting insulin and glucose, and improved glucose intolerance. Vascepa improved beta cell function, reduced liver triglycerides with enhanced expression of hepatic fatty acid oxidation genes, and altered microbiota composition. Vascepa has protective effects on diet-induced insulin resistance and glucose intolerance in mice.http://www.sciencedirect.com/science/article/pii/S2589004221008774Dietary supplementHuman metabolism |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Dana Al Rijjal Ying Liu Mi Lai Youchen Song Zahra Danaei Anne Wu Haneesha Mohan Li Wei Francisco J. Schopfer Feihan F. Dai Michael B. Wheeler |
| spellingShingle |
Dana Al Rijjal Ying Liu Mi Lai Youchen Song Zahra Danaei Anne Wu Haneesha Mohan Li Wei Francisco J. Schopfer Feihan F. Dai Michael B. Wheeler Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function iScience Dietary supplement Human metabolism |
| author_facet |
Dana Al Rijjal Ying Liu Mi Lai Youchen Song Zahra Danaei Anne Wu Haneesha Mohan Li Wei Francisco J. Schopfer Feihan F. Dai Michael B. Wheeler |
| author_sort |
Dana Al Rijjal |
| title |
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function |
| title_short |
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function |
| title_full |
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function |
| title_fullStr |
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function |
| title_full_unstemmed |
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function |
| title_sort |
vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function |
| publisher |
Elsevier |
| series |
iScience |
| issn |
2589-0042 |
| publishDate |
2021-08-01 |
| description |
Summary: Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes, and pancreatic beta cell function are not well understood. In the present study, mice were treated with Vascepa or Lovaza for one week prior to six weeks of high-fat diet feeding. Vascepa but not Lovaza led to reduced insulin resistance, reduced fasting insulin and glucose, and improved glucose intolerance. Vascepa improved beta cell function, reduced liver triglycerides with enhanced expression of hepatic fatty acid oxidation genes, and altered microbiota composition. Vascepa has protective effects on diet-induced insulin resistance and glucose intolerance in mice. |
| topic |
Dietary supplement Human metabolism |
| url |
http://www.sciencedirect.com/science/article/pii/S2589004221008774 |
| work_keys_str_mv |
AT danaalrijjal vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT yingliu vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT milai vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT youchensong vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT zahradanaei vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT annewu vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT haneeshamohan vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT liwei vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT franciscojschopfer vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT feihanfdai vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction AT michaelbwheeler vascepaprotectsagainsthighfatdietinducedglucoseintoleranceinsulinresistanceandimpairedbcellfunction |
| _version_ |
1721200255130664960 |